Morbid obesity is a significant health risk factor and its prevalence has increased in many industrialized countries in recent years. The principles of weight reduction have hardly changed over the years, but the range of approved drugs has expanded. Semaglutide and tirzepatide are the most commonly used today. Primary care providers play an important role in the individualized medical management of overweight patients.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
Related Topics
You May Also Like
- Omega-3 fatty acids for obesity and type 2 diabetes
More fish oil for better lipid and HbA1c levels
- MASLD often goes unnoticed and is underestimated
Think tank for improving the supply situation
- DGPPN Congress
People at the center of care
- Diagnostics of respiratory viral infections
What is tested when and on whom?
- Lung cancer
Multidisciplinary teams in oncology
- Seborrheic dermatitis in adults
Do not underestimate the symptom burden
- SGLT2 inhibitors
Clear, simple language improves patient safety
- Moderate to severe atopic dermatitis